Zydus Cadila gets USFDA nod for blood pressure drug
New Delhi: Zydus Cadila said it has received USFDA approval to market Triamterene and Hydrochlorothiazide tablets, indicated to treat high blood pressure.
The approval has been granted for the tablets in strengths of 37.5 mg/25 mg and 75 mg/50 mg.
“The combination drug is used for the treatment of high blood pressure. It is used by patients who have developed or are at risk for having low potassium levels on hydrochlorothiazide,” Zydus said in a BSE filing.
The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
The group now has more than 195 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in 2003-04.
Zydus Cadila discovers, develops, manufactures and markets a broad range of healthcare therapies.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd